| ORIGINAL ARTICLE |
|
| Year : 2023 | Volume
: 66
| Issue : 2 | Page : 264-268 |
|
|
Role of cyclin D1 in glial tumors—A retrospective and observational study
Ritu Mehta1, Rashmi Yadav2, Rahul Vatsgotra1
1 Department of Pathology, AFMC, Pune, Maharashtra, India
2 Department of Pathology, INHS, Asvini, Mumbai, India
Correspondence Address:
Rashmi Yadav
Department of Pathology INHS Asvini, Mumbai
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/IJPM.IJPM_1439_20
|
|
|
Aim: High-grade glial tumors remain as one of the most lethal malignancies. Cyclin D1 is expressed in some human malignancies and is the potential target of intervention. The present study aims to determine the relationship of cyclin D1 expression with other clinicopathological parameters. Materials and Methods: A cross-sectional study was carried out in a tertiary care center. Biopsy proven 66 cases of glial tumor patients were included in the study. The patients with incomplete clinical details were excluded from the study. Immunohistochemistry using antibodies for IDH 1 and cyclin d1 was done in all the cases. Glial tumors were reclassified according to WHO 2016 classification. Data analysis was performed using SPSS 26.0 for the windows. Result: Among 66 patients, 49 (74.3%) were males and 17 (25.7%) were females. The age of the patients ranged from 20 years to 70 years. Overall, 6.02% were of grade I Glial tumors, 22.7% were of grade II Glial tumors, 19.6% patients were of grade III Glial tumors, and 51.6% patients were of grade IV Glial tumors. Of 66 samples tested cyclin D1 was positive in 25 (37.87%) as high expressers and 7 (10.60%) were low expressers. Our study showed a significant correlation between the expression of cyclin D1 with grade and IDH mutation status, No significant correlation of cyclin D1 was noted with age or sex of the patient. Conclusion: Cyclin D1 was associated with a higher grade of the glial tumor. It can be a potential marker both for prognosis and treatment of glial tumors.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
